

## Original Article

# miR-223 inhibits tumor development of non-small cell lung cancer and sensitizes cancer cells to gefitinib via targeting E2F1

Zhi Zhou\*, Zili Meng\*, Yongqing Hong, Yaqiong Xiong

*Department of Respiratory, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, China. \*Equal contributors.*

Received November 16, 2016; Accepted February 4, 2017; Epub March 1, 2017; Published March 15, 2017

**Abstract:** MicroRNAs (miRNAs) are a class of short and non-coding RNA molecules that are capable of inhibiting translation of mRNAs of target genes. Previous studies have revealed that miRNAs are involved in the tumorigenesis and development of lung cancer. The Rnase-resistance of circulating miRNAs made it valuable non-invasive biomarkers and had attracted extensive research interests. The aim of the present study was to investigate the role of miR-223 in non-small cell lung cancer (NSCLC). The miRNA profiling showed a significantly differential expression of miR-205 and miR-223 between NSCLC tissue and normal adjacent tissues. Higher serum miR-233 level is corresponding to better survival, while miR-205 did not show difference regarding correlation of survival rate with its expression level. Using TargetScan predicting server, E2F1 was selected as a candidate target of miR-223, which was validated via luciferase assay. Further, overexpression of E2F1 counteracted the inhibitory effect of miR-223 on cell proliferation, and alleviates the proapoptosis by miR-223. Considering the deregulation of E2F1 had been reported in chemoresistant cells, we investigated the role of miR-223 in gefitinib challenged A549 cells. The tumor volume growth of mice injected with cells carrying lentivirus mediated miR-223 showed significantly decrease than control when both group treated with gefitinib on 15<sup>th</sup> day, which is consistent with survival analysis of those nude mice. These evidences point to the prospect of utilizing miR-223 in the prognosis of NSCLC patients under chemotherapy.

**Keywords:** Non-small cell lung cancer, miR-223, E2F1, gefitinib, chemoresistance

## Introduction

Lung cancer is one of the most lethal carcinomas among world population, which contributes to 27% of all cancer death [1]. Among various subtypes, non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and was considered as a refractory subtype, which is probably due to accumulation of mutations in RAS and p53 pathways [2]. Although substantial improvements have been made in diagnosis of lung cancer, the diagnosis rate is still undesired. Particularly, 25% of the diagnosed cases have already developed regional metastasis and 55% of them have distant metastasis, which made the therapy considerably intractable [3]. Indeed, with surgical resection at early stage, the 5-year survival rates is now approaching 70% [4]. However, there is still a demand of bet-

ter therapies and monitoring strategies for late-stage and aggressive disease that do not depend on particular mutations.

Previous studies revealed distinct protein-coding mutations as well as aberrantly expressed miRNAs profiles. miRNAs are 19-25 nucleotide-long endogenous noncoding RNAs which serve as critical components in regulating gene expression [5]. They bind to the target gene sequence with perfect or imperfect complementarity, thereby regulating the degradation or deterring the transcription of targets. Among those abnormally expressed miRNAs, let-7 and miR-34 are the most frequently reported miRNAs and the reduction of them in NSCLC is particularly associated with oncogenic phenotype of NSCLC, since they target key oncogenes implicated in multiple pathways that are contributory to tumorigenesis and maintenance of

oncologic properties, such as RAS, MET and MYC [6-8]. Recently, the Rnase-resistant circulating microRNAs (miRNAs) have garnered extensive attention, and were frequently reported as a promising component for early detection and prediction of outcomes of cancers [9]. According to recent estimation, about 50% of annotated human miRNAs are detected in tumor tissues, including lung cancer [10, 11]. Increasing evidence showed that subsets of miRNAs hold promise as diagnostic and prognostic biomarkers in malignancies [12]. Albeit some miRNAs have been recognized, considering the heterogeneity of NSCLC, novel discovery of potential biomarker is still needed.

In this study, we firstly performed miRNA profiling on tumor tissue and their adjacent normal tissues based on a pre-designed list of candidates, and identified miR-205 and miR-223 as research interest due to their significant fold changes between tumor and normal tissues. We then examined this finding in a cohort consisting of 126 patients and 100 normal controls, investigating the miR-223 and miR-205 content in their serum. Consequently, we found miR-223 has striking fold change between patients and normal control, while miR-205 showed much compromised absolute fold change. Furthermore, the individuals with high miR-223 expression presented higher survival rate than those with low miR-223 expression, and this was not observed in miR-205. Lentivirus-mediated overexpression of miR-223 respectively decreased the cell growth and increased the apoptosis, whereas silencing of miR-223 showed the opposite effect. Targetscan predicted E2F1 as a target of miR-223, which was validated by luciferase assay, as well as diminished E2F1 by overexpressing miR-223 and vice versa. As E2F1 has been highly implicated in drug resistance, we further investigated the effect of miR-223 on sensitivity of nude mice transplanted with miR-223 mimics and miR-223 antagomir overexpressing cells to gefitinib. Tumor size was significantly reduced in mice transplanted with miR-223 mimics overexpressing cells, and increased by xenografting cell overexpressing miR-223 antagomir. In addition, significantly elevated survival rate of miR-223 mimics overexpressing xenograft than control further support the hypothesis that miR-223 can be a promising prognostic biomarker.

## Material and methods


### *Patients and samples*

For miRNA expression level assay, three tumor-matched samples were obtained from NSCLC patients who received surgery in Huai'an People's First Hospital. For serum miRNA level experiments, 126 patients who were diagnosed with NSCLC at Huai'an People's First Hospital during from August, 2011 to September, 2014 were recruited. All studied patients were elder than 18 years of age, and had a pathological diagnosis of NSCLC as per histological or cytological criteria via biopsy or surgical resection. Those patients do not have a history of lung cancer, other cancers, or synchronous multiple cancers, never chemotherapy or radiotherapy before the blood were sampled. Tumor-node-metastasis (TNM) staging was performed as per relevant specification of American Joint Commission. Health control group recruited from the individuals taking physical examination at Healthy Physical Examination Center of Huai'an People's First Hospital. The checked items include chemistry profile, baseline electrolytes, blood cell counts, CEA and AFP, C-reactive protein, type-B ultrasound at abdomen and pelvis, and a chest X-ray. Individuals showed abnormality in any one of those items or have findings suggesting pulmonary pathology or constitutional symptoms were excluded. Written informed consents were obtained from patients and healthy individuals, followed by face-to-face interviews regarding demographic origins and locations, as well as exposure to smoking. The ever smokers were defined as those smoked one cigarette per day for over one year, and current smokers were those kept smoking.

### *RNA isolation and serum miRNA qRT-PCR assay*

Venous blood samples were collected and centrifuged at 800 g for 12 min at room temperature to separate serum. Another round of centrifugation at 10,000 g at room temperature for 15 min was performed to completely remove cell debris. Total RNA was extracted using Trizol Reagent (Invitrogen), which was then reversely transcribed to cDNA using AMV reverse transcriptase (Takara). Real-time PCR was conducted with Taqman miRNA probes. All experiments

# miR-223 inhibits tumor development of NSCLC through targeting E2F1



**Figure 1.** A. Profiling of miRNAs in NSCLC tissues. X axis represent absolute fold change of miRNAs between NSCLC tissues and normal adjacent tissues, y axis represents  $-\log_{10}$  transformed *p*-values calculated by t-test. B. Survival analysis on patients with high miR-205 expression and with low miR-205 expression in serum. X axis represents survival days and y axis indicates percentage of survival. C. Survival analysis on patients with high miR-223 expression and with low miR-223 expression in serum. X axis represents survival days and y axis indicates percentage of survival.

were performed triplicate. For miRNA level detection of tumor-matched samples, the relative amounts of miRNA were normalized to internal miRNA controls RNU6B. For serum miRNA level detection, Ct values were determined using the fixed threshold settings, which were then corrected according to standard amplification curve of series synthetic miRNA oligonucleotides of known concentrations. Since RNU6B can be degraded in serum, the

expression levels of miRNAs were directly normalized to total RNA.

## Cell culture and miRNAs transfection

The human non-small cell lung cancer cell line A549 was procured from Shanghai Institute of Cell Biology. The A549 cells were cultured in RPMI 1640 (Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum and 100 units/ml penicillin and 100  $\mu\text{g}/\text{ml}$  streptomycin (Invitrogen) at 37°C, 5%  $\text{CO}_2$  in humidified incubator. After growing to 70%~80% confluence, A549 cells were transfected with miR-223 mimics, antagomir or scramble sequence as control (Thermo Fisher Scientific, US) for 24 h at roomtemperature. Transfection was mediated by lentiviral vector GV259 (Shanghai GeneChem Co., Ltd.). The A549 cells were seeded at  $5 \times 10^4$  with  $2 \times 10^6$  lentivirus-transducing units in the presence of 10  $\mu\text{g}/\text{ml}$  polybrene in a 24-well plate. miR-223 mimics and miR-223 antagomir were synthesized by GenePharma (Shanghai, China). For drug-resistance assay, medium containing 0.1  $\mu\text{mol}/\text{L}$  gefitinib was used to replace the original medium after cell adhesion.

## Cell viability assay

A549 cells were seeded in 96-well plates at a density of  $2 \times 10^5$  cells/ $\text{cm}^2$  with 100  $\mu\text{l}$  cell culture medium. Cell viability was assessed using Cell Counting Kit 8 (CCK-8, Dojindo Laboratories) at different time points: 0 h, 24 h, 48 h and 72 h by a microplate reader by spectrophotometry at 450 nm.

## Western blot assay

Cells were lysed in NP-40 buffer containing 150 mM NaCl, 1.0% NP-40, 50 mM Tris-HCl and protease inhibitors (Roche) and 1 mM phenylmethyl sulfonylfluoride for 30 minutes on ice. The supernatant was subject to protein denaturation with buffer containing 2% sodium dodecylsulfate (SDS; Sigma), was subsequently analyzed using SDS-PAGE and monoclonal antibody against E2F1, PCNA and cleaved caspase-3. The resultant gel was then washed and covered by appropriate horseradish peroxidase-conjugated Ig secondary antibodies. Enhanced chemiluminescence (GE Healthcare) was used to detect the staining.

# miR-223 inhibits tumor development of NSCLC through targeting E2F1

**Table 1.** Characteristics of patients and their serum content of miR-223 and miR-205

Variable		NSCLC (n=126)	Control (n=100)	P-value
Age	≤60	55	45	0.893
	>60	71	55	
Smoking status	Female	23	21	0.866
	Current	67	51	
	Ever	28	23	
Histological types	Never	31	26	0.9472
	Adenocarcinoma	64		
	Squamous cell carcinoma	47		
Stage	Large cell carcinoma	15		0.2586
	I	35		
	II	11		
	III	52		
Other diseases	IV	28		0.2586
	None	117	98	
	Cardiac dysfunction	3		
	Active infection	5	2	
	Neurologic disorders	1		
miR-205		25.77±6.78	15.50±5.47	<0.001
miR-223		20.05±7.54	40.82±9.18	<0.001

## Apoptosis by flow cytometry

Annexin V and propidium iodide (PI) flow cytometry was used to measure apoptosis in fibroblasts. Fibroblasts were plated in 6-well plates at a density of  $2 \times 10^5$  cell/cm<sup>2</sup>. After 48 hrs transfection with miR-223 mimics and antagomirs, 100  $\mu$ L cells were suspended in  $1 \times$  Annexin-binding buffer and then incubated with 5  $\mu$ L fluorescein isothiocyanate (FITC) annexin V and 5  $\mu$ L PI (Invitrogen, US) for 15 min at room temperature in darkness. After adding 400  $\mu$ L to each replicate, the viability and apoptosis were analyzed by flow cytometry under 530 nm and >575 nm, respectively (BD Bioscience).


## Luciferase assay

E2F1 3'UTR and its mutated counterpart sequence plasmids were constructed. Cells were seeded in a 24-well plate at cell density of  $1 \times 10^5$  cells/well. After 24 hours of culture, cells were co-transfected with firefly luciferase reporter plasmids respectively containing wild-type or mutant E2F1 3'UTR pRL-TK vector expressing Renilla luciferase, and miR-223 or miRNA negative control via Lipofectamine 2000 (Invitrogen). Firefly and Renilla luciferase activities were measured after 36 hours by Dual Luciferase Reporter Assay (Promega, US).

Each transfection was performed twice in triplicate.

## In vivo experiments

Around 4-6 weeks old male nude mice were purchased from Shanghai Experimental Animal Center of the Chinese Academy of Sciences, which were housed under specific pathogen-free conditions at room temperature and less than 40% humidity. Excess food and water were provided. For tumor growth assay, 15 mice were randomly allocated to 3 groups: Control, Gefitinib treated, and miR-223+ Gefitinib. A total of  $2 \times 10^6$  control A549 cells and A549 cells overexpressing miR-223 were subcutaneously injected into the lower quadrant of the mice. When the tumor reached 80-90 mm<sup>3</sup>, gefitinib was intragastrically administered to each mouse for 16 days on daily basis. The tumor size was evaluated every 3 days for 4 weeks using calipers. The tumor volume was calculated as  $V = (\text{length} \times \text{width}^2) / 2$ . Further, to analyze the survival of different groups, 15 mice were randomly allocated into control, Gefitinib treated, and miR-223+ Gefitinib group. Gefitinib administration was conducted when the tumor size reached 70-90 mm<sup>3</sup>. After the mice suffered from limitations in activities and significant weight loss, they were sacrificed by cervical dislocation. All the animal raise and



**Figure 2.** A. Cell viability assay of A549 cells transfected with miR-223 mimics and miR-223 antagonism. X axis indicates time period after transfection, y axis represents cell counts multiplied by 10<sup>6</sup>. \*: P<0.05; \*\*: P<0.01 (t-test). B. Apoptosis assay of A549 cells transfected with miR-223 mimics and miR-223 antagonism. Y axis represents apoptosis percentage. \*: P<0.05; \*\*: P<0.01 (t-test), error bar: standard error. C. Representative example of Annexin V flow cytometry analysis. Y-axis indicates propidium iodide (PI) staining and x-axis shows Annexin V-FITC staining. Upper left quadrant represents necrosis, upper right shows late apoptosis and lower right shows early apoptosis.

experiment were approved by the Institutional Animal Care and Use Committee of Huai'an People's First Hospital.

#### Statistical analysis


Each biological replicate has three technical replicates to calculate the average value of each parameter. Data are reported as mean ± SD. Kaplan-Meier analysis was applied to analyze survival data. Student's t-test was used to test the significance of differences, and P<0.05 was considered significant.

#### Results

*miR-223 and miR-205 were differentially expressed between NSCLC and normal adjacent tissues*

We quantified 60 miRNAs in NSCLC and corresponding normal adjacent tissues to identify the miRNAs that were differentially expressed between them. Absolute fold change and p-value calculated based on t-test were used as measurement of differential expression. As shown in **Figure 1A**, miR-205 and miR-223 had

## miR-223 inhibits tumor development of NSCLC through targeting E2F1



**Figure 3.** A. Sequence of wild type E2F1 3' UTR, mutant E2F1 3' UTR, and miR-223. B. Relative luciferase activity of miR-223 mimic + E2F1 3'UTR WT vs. miR-223 mimic + E2F1 3'UTR MUT.  $**P < 0.01$ , vs. Scramble. C. Western blot of E2F1, PCNA, cleaved caspase-3 in A549 cells transfected with miR-223 mimic and miR-223 antagomir expressing vectors. D. Relative E2F1 mRNA level of A549 cells transfected with miR-223 mimic and miR-223 antagomir expressing vectors.

predominantly higher absolute fold changes. Further, the serum content of miR-205 and miR-223 were examined in 126 NSCLC patients and 100 normal people. The clinical characteristics of those patients were described in **Table 1**. The average age and smoking status were not significantly different between two groups. miR-205 was upregulated in the serum of NSCLC patients, while miR-223 was downregulated, both with fold change less than that found in between miRNA profiling of cancer and normal adjacent tissues.

To investigate if both miRNAs are correlated with survival rate, we performed Kaplan-Meier survival analysis on high miRNA expression and low miRNA expression patients, respectively. The survival rate of high and low miR-205 expression did not show significant difference ( $P$ -value = 0.6029 by Mantel-Cox test), whereas high miR-223 expressed patients have significantly higher survival rate than low miR-223 expressed patients ( $P$ -value = 0.0269 by Mantel-Cox test).

*Overexpression of miR-223 suppresses proliferation and promotes apoptosis of A549 cells*


In previous section, we demonstrated that miR-223, instead of miR-205, is associated with survival rate of NSCLC patients. However, more direct evidence implicating its suppressive role in progression of NSCLC are still needed. Thus, we used the human NSCLC cell line A549 transfected with miR-223 mimics and antagomirs to investigate whether miR-223 inhibit the progression of NSCLC cells. Cell proliferation and apoptosis were two events critical for cancer progression. Overexpression of miR-223 by transfecting miR-223 mimics resulted in reduced cell proliferation and higher apoptosis percentage in A549 cells, and down-regulation of

miR-223 by transfecting miR-223 antagomirs produced the opposite effects (**Figure 2A-C**).

### *E2F1 is a target of miR-223*

Since miRNAs function by mediating partial or entire degradation of mRNAs of target genes, determination of target genes are critical for elucidating the role of miR-223 in NSCLC. To address this, we adopted Targetscan, a tool based on searching for the presence of 8 mer, 7 mer, and 6 mer sites that match the seed region of each miRNA, to predict target genes

## miR-223 inhibits tumor development of NSCLC through targeting E2F1



**Figure 4.** A. Cell viability assay of A549 cells co-transfected with miR-223 mimics and E2F1 expressing vectors. X axis indicates time period after transfection, y axis represents cell counts multiplied by  $10^6$ . \*:  $P < 0.05$ ; \*\*:  $P < 0.01$  (t-test). B. Apoptosis assay of A549 cells co-transfected with miR-223 mimics and E2F1 expressing vectors. Y axis represents apoptosis percentage. \*:  $P < 0.05$ ; \*\*:  $P < 0.01$  (t-test), error bar: standard error. C. Western blot of E2F1, PCNA, cleaved caspase-3 in A549 cells co-transfected with miR-223 mimic and E2F1 expressing vectors.

of miR-223. Among the 412 transcripts, we chose E2F1 since it is a transcription factor and has been implicated in cancer development. E2F1-3'-UTR and E2F1-3'-UTR with mutation sequences plasmids were constructed (Figure 3A), then cotransfected with miR-223 mimic or scrambled control plasmids into A549 cells. After culturing for 24 hours, the fluorescent

intensity was detected. The miR-223+E2F1-3'-UTR WT group showed significantly higher luciferase activity than the miR-miR-223+E2F1-3'-UTR MUT group ( $P=0.00046$ ) (Figure 3B). Western blot results showed that the expression of E2F1 in A549 cells transfected with miR-223 mimics was obviously lower than those transfected with miR-223 antagonists and blank control (Figure 3C). mRNA expression level of E2F1 also present similar pattern (Figure 3D).

Based on the effect of miR-223 on cell proliferation and apoptosis, we selected biomarkers as molecular indication for evaluating the above biological processes: PCNA for cell proliferation and cleaved caspase-3 for apoptosis. Consistent with what was observed in A549 cells transfected with miR-223 mimics and antagonists, overexpression of miR-223 increased PCNA level and reduced the content of cleaved caspase-3 (Figure 3C).


### Overexpression of E2F1 counteracts the effect of miR-223 on proliferation and apoptosis

To further examine that the effect of miR-223 on cell proliferation and apoptosis was due to reduction of E2F1, overexpression of E2F1 in A549 cells was performed. The plasmids respectively carried miR-223 mimics and E2F1 were cotransfected into A549 cells. E2F1 overexpression was found to alleviate the inhibition of miR-223 mimics on cell proliferation, and the apoptosis rate was significantly reduced (Figure 4A, 4B), which is consistent with protein level of biomarkers detected by western blot (Figure 4C).

### miR-223 enhances the sensitivity of NSCLC to gefitinib in vivo

Since we have demonstrated that NSCLC patients with high miR-223 expression have significantly higher survival rate than the patients with low miR-223 expression, another question arise as we attempted to hypothesize that miR-223 could serve as a prognosis biomarker. Drug resistance is an important factor affecting the prognosis of cancer patients; therefore, we sought to investigate whether miR-223 could sensitize NSCLC to anti-cancer drugs. To address this question, an in vivo model was established by subcutaneous injection of miR-223-GV259 infected cells into mouse skins under left lower quadrants. All

## miR-223 inhibits tumor development of NSCLC through targeting E2F1



**Figure 5.** A. Growth curves of tumors in 3 groups: Control, Control + gefitinib, and miR-223 mimic + gefitinib (\* $P < 0.05$ ), gefitinib was administrated on 15<sup>th</sup> day for 2 weeks for Control + gefitinib and miR-223 mimic + gefitinib groups. B. Survival curves of nude mice in 3 groups. Gefitinib was administrated on 15<sup>th</sup> day for 2 weeks for Control + gefitinib and miR-223 mimic + gefitinib groups.

mice were divided into 3 groups: control, control + gefitinib and miR-223+ gefitinib, and tumor sizes were measured every 3 days. Except control group, control + gefitinib and miR-223+ gefitinib group were intragastrically administrated with gefitinib from 15<sup>th</sup> day for 2 weeks. miR-223+ gefitinib group were injected with miR-223-GV259 and treated with gefitinib on 15<sup>th</sup> day for 2 weeks. Gefitinib exerts anti-cancer effect on both groups, and miR-223+ gefitinib has significantly lower tumor volumes than control + gefitinib (**Figure 5A**). In survival analysis, the miR-223+ gefitinib group presented significantly higher percentage of survival than control and even control + gefitinib group. These findings indicate that miR-223 enhances the sensitivity of NSCLC to gefitinib, which may provide valuable reference for research community as well as clinical practitioners.

### Discussion

The important roles of miRNAs have been indicated in multiple lines of studies investigating tumor initiation and progression [13-17]. The

deregulation of miRNAs is highly implicated in cancer biology. miR-223 was reported in hematopoietic system for the first time [18], which initiated subsequent characterization of its biological functions. Previous studies revealed that miR-223 was down-regulated in human embryonic stem cells, nasopharyngeal cancer cells, and HeLa cells [19-21]. In addition, the inhibitory role of miR-223 in cell proliferation, colony formation and migration were further investigated and determined [21, 22]. In lung cancer, the anti-oncogenic role of miR-223 has also been characterized. In the present study, we observed a significant higher fold change of miR-223 against control in the serum blood of NSCLC patients, compared with other miRNAs in the profiling.

E2F transcription factors are situated downstream of growth factor signaling cascades, and regulate genes required for cell

cycle progression by acting as transcriptional activators or suppressor. Therefore, the role of E2Fs in tumor initiation and development is ambivalent: both oncogenic and suppressive depending on the cellular context. E2F1 was recognized as a potent regulator of apoptosis when DNA damage occurs in various type of human cancer [23]. It was reported that tumor cells, especially from advanced lesions may survive diminished cell death pathways when E2F1 was deregulated in the absence of RB [24] a cell-death effector that acts with cytochrome c and caspase-9 to mediate p53-dependent apoptosis. Loss of Apaf-1 expression is accompanied by allelic loss in metastatic melanomas, but can be recovered in melanoma cell lines by treatment with the methylation inhibitor 5-aza-2'-deoxycytidine (5aza2dC. Previous studies revealed that E2F1 is a tumor suppressor in colon carcinomas [25]. However, it is suggested that overexpression of E2F1 may result in gene amplification, which confers proliferative advantage to the tumor cells in lung and liver colon cancer metastasis [26]  $n=9$ . Abnormal expression of E2F1 or aberrant amplifica-



tion of E2F1 gene has been implicated in a variety of human cancers. Multiple lines of studies suggested that elevated E2F1 expression was predominantly associated with advanced tumor stages and metastasis status, as well as poor prognosis. In bladder cancer, Lee and colleagues established a model taking account of expression of E2F1 and the associated genes to predict the progression of tumor [27]. Alla *et al.* employed E2F1 knockdown mice to elucidate the effect of E2F1 on skin cancer, and found that endogenous E2F1 deficiency dramatically reduced the migratory and invasive ability of tumors, but the proliferation seemed independent of this change [28]. Recently, the role of E2F1 in small cell lung cancer was also suggested. Li *et al.* observed the expression of ADAM12, a protein highly expressed in small cell lung cancer, was significantly decreased following silencing of E2F1 by siRNA, which was proved to function via changes in the E2F1 binding to differential cis-acting elements of ADAM1 [29]. In the present study, E2F1 was a candidate of miR-223 targets by TargetScan, which may explain the anti-proliferative function of miR-223. This was further confirmed by luciferase assay, concordantly decreased cell growth rate and E2F1 expression in cells transfected with miR-223. Our study complements the profile of the biological functions of E2F1 in various cell lines.

Apart from the important role in metastasis, E2F1 may also be one of the determinants of chemoresistance [30]. Indeed, Jesper *et al.* revealed that zebularine-resistant hepatocellular carcinoma cell lines showed up-regulation of key oncogenic networks (TNF, MYC, VHL, and CDKN2A), in which E2F1 was overrepresented, suggesting that their activation by E2F1 may be critical for the development of zebularine resistance [31] we report a comprehensive characterization of epigenomic modulation caused by zebularine, an effective DNA methylation inhibitor, in human liver cancer. Using transcriptomic and epigenomic profiling, we identified a zebularine response signature that classified liver cancer cell lines into two major subtypes with different drug responses. In drug-sensitive cell lines, zebularine caused inhibition of proliferation coupled with increased apoptosis, whereas drug-resistant cell lines showed up-regulation of oncogenic networks (for example, E2F1, MYC, and TNF). It is reasonable to infer that miR-223, as a regulator of E2F1, may also serve as

mediator of chemoresistance. In the present study, the overexpression of miR-223 sensitized the A549 to gefitinib, which can be inferred from the smaller tumor size of mice injected with cells carrying lentivirus-mediated miR-223. Furthermore, the mice injected with miR-223 overexpressing cells have a higher survival rate than control. This finding is in alignment with a recent study investigating into the enhancement of sensitivity of non-small cell lung cancer cells to erlotinib by miR-223 [32], and our study adds to the jigsaw puzzle of the functional profile of miR-223 in chemoresistance.

In conclusion, the present study hypothesized that miR-223 can inhibit the proliferation and induce apoptosis of NSCLC cells by targeting E2F1. The reduced resistance to gefitinib in miR-223 overexpressing cells demonstrated that miR-223 not only serves as a potential biomarker for prognosis but also an indicator for medication of gefitinib, in which the molecular mechanisms were elucidated by involvement of downregulation of E2F1 in cell proliferation and apoptosis. The survival analysis of mice transfected with lentivirus-mediated miR-223 further supports this hypothesis.

### Disclosure of conflict of interest

None.

**Address correspondence to:** Yaqiong Xiong, Department of Respiratory, Huai'an First People's Hospital, Nanjing Medical University, No. 6 Beijing Road West, Huai'an 223300, Jiangsu, China. E-mail: yq\_xiong@sina.cn

### References

- [1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin* 2015; 65: 5-29.
- [2] Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. *Mayo Clin Proc* 2008; 83: 584-594.
- [3] Spiro SG, Gould MK, Colice GL; American College of Chest Physicians. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). *Chest* 2007; 132 Suppl: 149S-160S.
- [4] National Lung Screening Trial Research Team, Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, Gareen IF, Gatsonis C,

## miR-223 inhibits tumor development of NSCLC through targeting E2F1

- Goldin J, Gohagan JK, Hillman B, Jaffe C, Kramer BS, Lynch D, Marcus PM, Schnall M, Sullivan DC, Sullivan D, Zylak CJ. The national lung screening trial: overview and study design. *Radiology* 2011; 258: 243-53.
- [5] Gomes CC, de Sousa SF, Gomez RS. MicroRNAs: small molecules with a potentially role in oral squamous cell carcinoma. *Curr Pharm Des* 2013; 19: 1285-1291.
- [6] Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. RAS is regulated by the let-7 microRNA family. *Cell* 2005; 120: 635-647.
- [7] Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, MacDougald OA, Cho KR, Fearon ER. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. *Curr Biol* 2007; 17: 1298-1307.
- [8] Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, Tsang P, Zhang Q, Thiele CJ, Slack A, Shoheit J, Khan J. The MYCN oncogene is a direct target of miR-34a. *Oncogene* 2008; 27: 5204-5213.
- [9] Giordano S, Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? *Hepatology* 2013; 57: 840-847.
- [10] Li L, Qiu XG, Lv PW, Wang F. miR-639 promotes the proliferation and invasion of breast cancer cell in vitro. *Cancer Cell Int* 2014; 14: 39.
- [11] Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. *Oncogene* 2008; 27: 5959-74.
- [12] Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, He QM, Jiang N, Chen L, Cho WC, Yun JP, Zeng J, Liu LZ, Li L, Guo Y, Wang HY, Ma J. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. *Lancet Oncol* 2012; 13: 633-641.
- [13] Pullen TJ, da Silva Xavier G, Kelsey G, Rutter GA. miR-29a and miR-29b contribute to pancreatic beta-cell-specific silencing of monocarboxylate transporter 1 (Mct1). *Mol Cell Biol* 2011; 31: 3182-3194.
- [14] Lehrbach NJ, Armisen J, Lightfoot HL, Murfitt KJ, Bugaut A, Balasubramanian S, Miska EA. LIN-28 and the poly(U) polymerase PUP-2 regulate let-7 microRNA processing in *Caenorhabditis elegans*. *Nat Struct Mol Biol* 2009; 16: 1016-1020.
- [15] Dalmay T, Edwards DR. MicroRNAs and the hallmarks of cancer. *Oncogene* 2006; 25: 6170-6175.
- [16] Song SJ, Poliseno L, Song MS, Ala U, Webster K, Ng C, Beringer G, Brikbak NJ, Yuan X, Cantley LC, Richardson AL, Pandolfi PP. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. *Cell* 2013; 154: 311-324.
- [17] Hurteau GJ, Carlson JA, Spivack SD, Brock GJ. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. *Cancer Res* 2007; 67: 7972-7976.
- [18] Kapinas K, Delany AM. MicroRNA biogenesis and regulation of bone remodeling. *Arthritis Res Ther* 2011; 13: 1-11.
- [19] Yu YH, Zhang L, Wu DS, Zhang Z, Huang FF, Zhang J, Chen XP, Liang DS, Zeng H, Chen FP. MiR-223 regulates human embryonic stem cell differentiation by targeting the IGF-1R/Akt signaling pathway. *PLoS One* 2013; 8: e78769.
- [20] Zeng X, Xiang J, Wu M, Xiong W, Tang H, Deng M, Li X, Liao Q, Su B, Luo Z. Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. *PLoS One* 2012; 7: e46367.
- [21] Jia CY, Li HH, Zhu XC, Dong YW, Fu D, Zhao QL, Wu W, Wu XZ. MiR-223 suppresses cell proliferation by targeting IGF-1R. *PLoS One* 2011; 6: e27008.
- [22] Jin C, Samuelson L, Cui CB, Sun Y, Gerber DA. MAPK/ERK and Wnt/ $\beta$ -catenin pathways are synergistically involved in proliferation of Sca-1 positive hepatic progenitor cells. *Biochem Biophys Res Commun* 2011; 409: 803-807.
- [23] Engelmann D, Pützer BM. The dark side of E2F1: In transit beyond apoptosis. *Cancer Res* 2012; 72: 571-575.
- [24] Soengas MS, Capodiceci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardó C, Lowe SW. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. *Nature* 2001; 409: 207-211.
- [25] Christensen LL, Tobiasen H, Holm A, Schepeler T, Ostenfeld MS, Thorsen K, Rasmussen MH, Birkenkamp-Demtroeder K, Sieber OM, Gibbs P. MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer. *Int J Cancer* 2013; 133: 67-78.
- [26] Iwamoto M, Banerjee D, Menon LG, Jurkiewicz A, Rao PH, Kemeny NE, Fong Y, Jhanwar SC, Gorlick R, Bertino JR. Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplification. *Cancer Biol Ther* 2004; 3: 395-399.
- [27] Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, Kim SK, Kim YJ, Kim WJ, Chu IS. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. *J Clin Oncol* 2010; 28: 2660-2667.

## miR-223 inhibits tumor development of NSCLC through targeting E2F1

- [28] Alla V, Engelmann D, Niemetz A, Pahnke J, Schmidt A, Kunz M, Emmrich S, Steder M, Koczan D, Pützer BM. E2F1 in melanoma progression and metastasis. *J Natl Cancer Inst* 2010; 102: 127-33.
- [29] Li Z, Wang Y, Kong L, Yue Z, Ma Y, Chen X. Expression of ADAM12 is regulated by E2F1 in small cell lung cancer. *Oncol Rep* 2015; 34: 3231-3237.
- [30] Engelmann D, Knoll S, Ewerth D, Steder M, Stoll A, Putzer BM. Functional interplay between E2F1 and chemotherapeutic drugs defines immediate E2F1 target genes crucial for cancer cell death. *Cell Mol Life Sci* 2010; 67: 931-948.
- [31] Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D, Conner EA, Thorgeirsson SS. An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. *Sci Transl Med* 2010; 2: 54ra77.
- [32] Zhao F, Han J, Chen X, Wang J, Wang X, Sun J, Chen Z. miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor. *Int J Mol Med* 2016; 38: 183-91.